Franco Locatelli, MD, PhD, head of the Department of Pediatric Hematology and Oncology at IRCCS Bambino Gesu Children’s Hospital in Rome, discusses the treatment of both adult and pediatric patients ...
Franco Locatelli, MD, PhD, a professor and hematologist from Italy, discusses results from the the phase 2 REACH 5 studies assessing the use of ruxolitinib in pediatric patients with chronic graft ...
Please provide your email address to receive an email when new articles are posted on . Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy ...
Immunotherapy with a chimeric antigen receptor (CAR) T-cell treatment targeting disialoganglioside GD2 may have a sustained antitumor effect in at least a proportion of pediatric patients with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...
Anti-disialoganglioside (GD2)-targeted third-generation chimeric antigen receptor T cells (GD2-CART01) have shown promising efficacy in children with high-risk metastatic, relapsed, and refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results